Binds Receptor (e.g., Transferrin Receptor, Fc Receptor, Dihydropyridine Receptor, Il-2 Receptor, Etc.) Patents (Class 530/388.22)
-
Patent number: 8759009Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: GrantFiled: August 17, 2010Date of Patent: June 24, 2014Assignee: Glenmark Pharmaceuticals S.A.Inventors: Elias Lazarides, Catherine Mary Woods, Mark Bernard
-
Patent number: 8758756Abstract: An anti-human epidermal growth factor receptor (EGFR) antibody including an amino acid sequence as set forth in SEQ ID No. 3 is provided. The antibody binding to a labeling agent and used for labeling cells is also provided. A novel method for screening an anti-EGFR antibody is further provided.Type: GrantFiled: September 12, 2012Date of Patent: June 24, 2014Assignee: Industrial Technology Research InstituteInventors: Hsiang-Ching Wang, Ming-Hua Yang, Ling-Mei Wang, Min-Yuan Chou, Jyuan-Jyuan Syu
-
Patent number: 8759297Abstract: Provided herein are compositions for increasing transport of agents across the blood-brain barrier, in some embodiments in both directions, while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood-brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agent. Also provided herein are nucleic acids encoding proteins contained in the compositions.Type: GrantFiled: August 20, 2007Date of Patent: June 24, 2014Assignee: ArmaGen Technologies, Inc.Inventors: William M. Pardridge, Ruben J. Boado
-
Publication number: 20140170168Abstract: Provided are isolated high affinity entities which comprise an antigen binding domain which specifically binds a soluble T-cell receptor ligand comprising a two-domain beta1-alpha1 of a major histocompatibility complex (MHC) class II, wherein said antigen binding domain does not bind a complex comprising a four-domain alpha1-beta1/alpha2-beta2 MHC class II. Also provided are methods and kits using same for detecting and sequestering soluble two-domain T cell receptor ligands in a sample.Type: ApplicationFiled: October 26, 2011Publication date: June 19, 2014Inventors: Yoram Reiter, Rony Dahan, Arthur A. Vandenbark
-
Patent number: 8753637Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: GrantFiled: December 28, 2011Date of Patent: June 17, 2014Assignee: RSR LimitedInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Patent number: 8753631Abstract: The present invention is directed to a therapeutic agent comprising a GPIIIa(49-66) specific targeting agent and a thrombi-specific homing agent. Also disclosed is the use of the therapeutic agent in carrying out a method of treating thromboembolic disorders and a method of inducing platelet fragmentation.Type: GrantFiled: April 30, 2010Date of Patent: June 17, 2014Assignee: New York UniversityInventors: Simon Karpatkin, Michael Nardi, Zongdong Li
-
Patent number: 8754035Abstract: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.Type: GrantFiled: February 16, 2010Date of Patent: June 17, 2014Assignee: Oncolix, Inc.Inventor: Wen Y. Chen
-
Patent number: 8748585Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.Type: GrantFiled: July 10, 2012Date of Patent: June 10, 2014Assignee: Glenmark Pharmaceuticals S.A.Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
-
Patent number: 8748107Abstract: The present invention provides antibodies which bind to CXC chemokine receptor 4 (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: February 10, 2011Date of Patent: June 10, 2014Assignee: Affitech Research ASInventors: Anita Kavlie, Sergej Michailovic Kiprijanov
-
Patent number: 8748175Abstract: Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.Type: GrantFiled: November 2, 2009Date of Patent: June 10, 2014Assignee: Green Cross CorporationInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Yong Nam Shin, Kyung Hwan Ryoo, Dong Hyuck Seo, Jong-Hwa Won, Min-Kyu Hur
-
Patent number: 8741586Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: December 6, 2010Date of Patent: June 3, 2014Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
-
Publication number: 20140148584Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.Type: ApplicationFiled: October 16, 2013Publication date: May 29, 2014Applicants: XOMA Technology Ltd., Novartis AGInventors: Jeff Hsu, Linda Masat, Judy Abraham, Masahisa Handa, Siew Schleyer
-
Publication number: 20140147556Abstract: The present technology provides, in one aspect, an edible or inhalable composition including an isolated “antagonist ligand” or an isolated “antagonist antibody” or an antigen-binding fragment thereof, which specifically binds a taste receptor ligand or an olfactory receptor ligand. Foods and intranasal formulations containing the above-described compositions are described, as are methods of use.Type: ApplicationFiled: November 27, 2012Publication date: May 29, 2014Applicant: Elwha LLCInventors: Maxime J. J. Bilet, Ilya Fushman, Roderick A. Hyde, Jordin T. Kare, Vinod Khosla, David Mann, Nathan P. Myhrvold, Clarence T. Tegreene, Lowell L. Wood, JR., Christopher C. Young
-
Patent number: 8734800Abstract: An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH2 (447), and an antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH2 (447), and a pharmaceutical composition comprising them.Type: GrantFiled: December 20, 2012Date of Patent: May 27, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Katsuhiro Kano, Isamu Terashima
-
Patent number: 8734790Abstract: This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.Type: GrantFiled: January 10, 2012Date of Patent: May 27, 2014Assignee: Novimmune SAInventors: Marie Kosco-Vilbois, Katrien L. De Graaf, Thierry Berney, Laurianne Santa Giovannoni, Domenic Bosco
-
Patent number: 8734798Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.Type: GrantFiled: October 27, 2010Date of Patent: May 27, 2014Assignee: UCB Pharma S.A.Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J Wolff
-
Patent number: 8735552Abstract: The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.Type: GrantFiled: March 10, 2010Date of Patent: May 27, 2014Assignees: Gene Techno Science Co., Ltd., Kaken Pharmaceutical Co.Inventors: Shankar Kumar, J. Yun Tso, Naoya Tsurushita, Tatsuhiro Harada
-
Patent number: 8735551Abstract: The present invention relates to antibodies or fragments thereof that target a conformational epitope of a HER receptor. In particular, the invention relates to antibodies or fragments thereof that target a conformational epitope of HER3 receptor and compositions and methods of use thereof.Type: GrantFiled: August 22, 2011Date of Patent: May 27, 2014Assignee: Novartis AGInventors: Andrew Paul Garner, Elizabeth Anne Reisinger Sprague, Seth Alexander Ettenberg, Christian Kunz, Nicole Haubst, Winfried Elis
-
Patent number: 8735095Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.Type: GrantFiled: November 16, 2012Date of Patent: May 27, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
-
Patent number: 8734794Abstract: A fully humanized antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.Type: GrantFiled: July 6, 2010Date of Patent: May 27, 2014Assignee: Opsona Therapeutics LimitedInventor: Jerome Dellacasagrande
-
Patent number: 8735553Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.Type: GrantFiled: November 10, 2013Date of Patent: May 27, 2014Assignee: Beigene, Ltd.Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
-
Patent number: 8735545Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.Type: GrantFiled: June 19, 2007Date of Patent: May 27, 2014Assignee: Xencor, Inc.Inventors: Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
-
Patent number: 8728740Abstract: Epitopes localized on FNIII-8 repeat that are normally cryptic but are unmasked by insertion of FNIII-B into the FN molecule and are recognized by specific ligands are described; antibodies or their fragments able to identify the above said epitope are also described.Type: GrantFiled: December 11, 2009Date of Patent: May 20, 2014Assignee: Sirius-Biotech S.R.L.Inventors: Patrizia Castellani, Francesca Sassi, M. Barbara Carnemolla, Laura Borsi, Enrica Balza
-
Patent number: 8728473Abstract: Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.Type: GrantFiled: December 1, 2011Date of Patent: May 20, 2014Assignee: Alderbio Holdings LLCInventors: Leon F. Garcia-Martinez, John A. Latham, Ethan W. Ojala, Corinne C. Akatsuka, Pei Fan, Jeffrey T. L. Smith, Benjamin H. Dutzar
-
Publication number: 20140134179Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: ApplicationFiled: June 13, 2012Publication date: May 15, 2014Applicants: Novartis AG, The United States of America, as represented by the Sec., Dept of Health and Human ServicesInventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong
-
Patent number: 8722047Abstract: The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.Type: GrantFiled: April 5, 2010Date of Patent: May 13, 2014Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, Chien-Hsing Chang
-
Patent number: 8722051Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2012Date of Patent: May 13, 2014Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Patent number: 8722857Abstract: The present invention is directed to cysteine-engineered anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: January 14, 2009Date of Patent: May 13, 2014Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
-
Publication number: 20140127223Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.Type: ApplicationFiled: April 27, 2012Publication date: May 8, 2014Applicant: SBI BIOTECH CO., LTD.Inventors: Tomohide Yamazaki, Jing Zhao, Koji Ishida, Yasue Shibata, Minkwon Cho, Mayuki Endo
-
Publication number: 20140130191Abstract: The invention relates to a compound comprising non-peptide prokineticin receptors antagonists and agents that modulate or inhibit the activity of prokineticin receptors for use in the treatment of immune-mediated diseases of the central nervous system, peripheral nervous system and neuromuscular junctions.Type: ApplicationFiled: June 27, 2012Publication date: May 8, 2014Applicant: FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO "CARLO BESTA"Inventors: Rosetta Pedotti, Mohamad Abou Hamdan
-
Publication number: 20140127207Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.Type: ApplicationFiled: January 3, 2014Publication date: May 8, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
-
Patent number: 8715655Abstract: The present invention provides a human anti-?9 integrin antibody or an antibody fragment which specifically recognize human ?9 integrin and mouse ?9 integrin, inhibit interaction with their ligands, particularly, the antibody or antibody fragment which recognize loop regions of human and mouse ?9 integrins, a gene encoding the antibody or antibody fragment, a recombinant expression vector containing the gene, a transformant harboring the gene, production method of human anti-?9 integrin antibody or antibody fragment using the transformant, and an agent for the prophylaxis or treatment of rheumatoid arthritis which contains the antibody or antibody fragment.Type: GrantFiled: December 26, 2008Date of Patent: May 6, 2014Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Masaharu Torikai, Daisuke Ishikawa, Toshihiro Nakashima, Hirofumi Higuchi, Fumihiko Sakai, Nobuchika Yamamoto, Hirotada Fujita, Katsunari Taguchi
-
Patent number: 8715666Abstract: According to the invention there is provided use of an anti-TrkA antibody capable of inhibiting the binding between NGF and TrkA combined with at least one opioid analgesic for the preparation of a medicament for treating and/or preventing pain.Type: GrantFiled: June 23, 2011Date of Patent: May 6, 2014Assignee: Lay Line Genomics S.p.A.Inventors: Flaminia Pavone, Sara Marinelli, Antonio Cattaneo, Gabriele Ugolini
-
Patent number: 8715657Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R?2 chain) as well as IL23 receptor (together with IL23R? chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: GrantFiled: March 29, 2010Date of Patent: May 6, 2014Assignee: Novartis AGInventors: Michael Bardroff, Jose M. Carballido Herrera, Daniela Della Ducata, Christoph Heusser, Ute Jaeger, Christoph Schwaerzler
-
Patent number: 8715668Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: September 17, 2012Date of Patent: May 6, 2014Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Patent number: 8715670Abstract: The present invention relates to a human monoclonal antibody that specifically binds to VCAM-1, and a therapeutic composition for the treatment of inflammatory disease or cancer comprising the same. The human monoclonal antibody according to the present invention shows a strong affinity to VCAM-1 expressed on human or mouse endothelial cell, effectively inhibits leukocyte adhesion to activated endothelial cells expressing VCAM-1, and shows a low immunogenicity, thereby being used for the treatment of cancer or inflammatory disease such as asthma, rhinitis, arthritis, multiple sclerosis, bowel disease, arteriosclerosis, myocardial infarction and transplant rejection.Type: GrantFiled: March 31, 2010Date of Patent: May 6, 2014Assignee: Hanwha Chemical CorporationInventors: Jung Tae Lee, Kyung Duk Moon, Ji Yong Yoon, Byung Je Sung, Dong Heon Lee, Il Sun Lee, Dong Eun Lee, Su Yeon Ryu, Young Woo Park, So Young Choi, Ji Hyun Park, Myeoung Hee Jang
-
Patent number: 8710194Abstract: The present invention relates to a single-chain variable fragment (scFv) able to recognize an epitope of the extracellular domain of CD99 human protein. The single-chain variable fragment is able to recognize and specifically and selectively bind the epitope of the extracellular domain of CD99 human protein expressed on Ewing sarcoma cells. The fragment can thus be used for the diagnosis and 10 treatment of Ewing sarcoma.Type: GrantFiled: November 12, 2010Date of Patent: April 29, 2014Assignee: Istituto Ortopedico RizzoliInventors: Piero Picci, Katia Scotlandi, Alessandro Ascione, Maurizio Cianfriglia, Maria Luisa Dupuis, Michela Flego, Mara Gellini, Alessandra Mallano
-
Patent number: 8709424Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.Type: GrantFiled: August 31, 2010Date of Patent: April 29, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
-
Patent number: 8709426Abstract: The present invention relates to new nucleotide sequences coding for variable regions of ? chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.Type: GrantFiled: October 5, 2007Date of Patent: April 29, 2014Assignee: Aventis Pharma S.A.Inventors: Thierry Hercend, Frederic Triebel, Sergio Roman-Roman, Laurent Ferradini
-
Patent number: 8709425Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.Type: GrantFiled: February 13, 2013Date of Patent: April 29, 2014Assignee: Biosceptre International LimitedInventors: Julia Alexander Barden, Angus Gidley-Baird
-
Patent number: 8710191Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.Type: GrantFiled: August 17, 2009Date of Patent: April 29, 2014Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Publication number: 20140112931Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.Type: ApplicationFiled: May 21, 2012Publication date: April 24, 2014Applicants: UNIVERSITE DE MONTPELLIER 1, CENTRE VAL D'AURELLE - PAUL LAMARQUEInventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
-
Publication number: 20140112942Abstract: The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 5, 6 and 7, or a variant of any of said sequences; and/or an antibody light chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 8, 9 and 10, or a variant of any of said sequences.Type: ApplicationFiled: March 11, 2013Publication date: April 24, 2014Applicant: BIONOVION HOLDING B.V.Inventors: Hans Van Eenennaam, Winfried Robert Mulder, Jannetje Geertruida Borst, Aartje Maria Elizabeth Veraar, Paul Maria Frederikus Vink
-
Publication number: 20140115727Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: August 29, 2013Publication date: April 24, 2014Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cedric Bes
-
Patent number: 8703149Abstract: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.Type: GrantFiled: August 23, 2011Date of Patent: April 22, 2014Assignee: The Rockefeller UniversityInventors: Charles Rice, Matthew J. Evans, Thomas Von Hahn
-
Patent number: 8703129Abstract: Disclosed herein are antibodies or antigen-binding portions thereof directed against extended Type I chain antigens, in particular extended Type I chain glycosphingolipids, and the uses of the antibodies or antigen-binding portions thereof in the diagnosis, amelioration, treatment or prevention of diseases or disorders in mammals, including humans, resulting from or associated with the improper activity/metabolism or the presence of extended Type I chain antigens, in particular extended Type I chain glycosphingolipids.Type: GrantFiled: March 29, 2012Date of Patent: April 22, 2014Assignee: GlycoNex, Inc.Inventors: Tong-Hsuan Chang, Jerry Ting, Mei-Chin Yang, Liahng-Yirn Liu, Shu-Yen Chang, Chia-Hao Chang
-
Patent number: 8703125Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention further-more relates to methods of altering expression of said receptors in vivo.Type: GrantFiled: December 17, 2009Date of Patent: April 22, 2014Assignee: H. Lundbeck A/SInventors: Simon Glerup Pedersen, Ulrich Bølcho, Kimmo Jensen, Anders Nykjær
-
Publication number: 20140105821Abstract: A monoclonal antibody is described herein specifically binding to domains II and IIIc of FGFR1 or to a complex of fibroblast growth factor receptor type 1 and heparan sulphate. A method is proposed for suppressing tumour growth, based on blocking the human fibroblast growth factor/human fibroblast growth factor receptor type 1 (domains II and IIIc) pathway and involves administering the antibody. A conjugate of the antibody and contrast agents is proposed intended for use in diagnosing malignant and other growths, whose cells express large quantities of FGFR1. A method is proposed for diagnosing malignant neoplasms. The proposed methods enable blocking the fibroblast growth factor/fibroblast growth factor receptor type 1 pathway by means of binding to domains II and IIIc of FGFR1, thus stopping or slowing tumour growth. The methods present novel preparations for the diagnosis and treatment of diseases related to overproliferation and neovascularization.Type: ApplicationFiled: March 30, 2011Publication date: April 17, 2014Inventor: llya Valer'evich Tymofeev
-
Publication number: 20140105898Abstract: This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of TRAIL death receptor agonists, including nucleic acids such as TRAIL polynucleotides, peptides and polypeptides including TRAIL polypeptides, TRAIL DR agonist antigen-binding molecules, TRAIL DR peptide agonists as well as small molecule TRAIL DR agonists in compositions and methods for treating or preventing adiposity-related conditions such as obesity, diabetes mellitus and metabolic syndrome.Type: ApplicationFiled: February 27, 2012Publication date: April 17, 2014Applicant: Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo GaroInventors: Merlin C. Thomas, Giorgio Zauli, Paola Secchiero, Bruno Fabris, Stella Bernardi
-
Patent number: 8691233Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: GrantFiled: March 10, 2010Date of Patent: April 8, 2014Assignee: UCB Pharma S.A.Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson